지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.6
- 수록면
- 45 - 57 (13page)
이용수
초록· 키워드
오류제보하기
Objectives: This study aimed to investigate the trends in insurance-reimbursed biologics using the Korean National Health Insurance Claims Database (KNHICD) from 2012 to 2021. Methods: We analyzed the utilization, expenditure, and market share of listed biologics, which were classified as original, original line extension, biosimilar, and biosimilar line extension. Utilization was calculated using treatment days (TDs) defined as the dose of the active ingredient of the biologics divided by daily defined dose. Results: Total expenditure of biologics increased approximately doubled from KRW 279.3 billion in 2012 to KRW 533.6 billion in 2021, and utilization increased approximately 2.5 times from 13.4 million TDs in 2012 to 34.3 million TDs in 2021. The expenditures and utilization of originals have decreased since 2017, while those of biosimilars and original line extension have increased. For immunosuppressants, the proportion of original decreased the most, but original line extension filled the gap. For anticancer agents, reimbursement for biosimilars have caused in a decrease in the proportion of original line extension, which had been increasing previously. The market shares of other treatment agents biosimilar was lower than the other treatment group. The utilization of biosimilars varies by treatment agents group, depending on the prescription classifications, medical institution type, medical department. Conclusion: The annual total expenditure and utilization of biologics are increasing gradually. However, the expenditure on originals for most treatment types decreased after biosimilars were included in insurance coverage. These results demonstrate the market substitute effect of biosimilars and the potential financial savings of health insurance due to the increasing proportion of utilization and expenditures for biosimilars accompanied by decreasing utilization and expenditures for original biologics. Meanwhile, original line extensions have been developed to maintain a portion of the market share against biosimilars. Reflecting these findings, appropriate policies are needed to promote the rational use of biologics.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
Intestinal research
2020 .01
-
A therapeutic equivalence study of biologic agent and biosimilar in LPS-stimulated RAW264.7 macrophages
한국실험동물학회 학술발표대회 논문집
2015 .02
-
Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea
Journal of Korean Medical Science
2021 .01
-
Immunotherapy; monoclonal antibody; successful biosimilars development
한국실험동물학회 학술발표대회 논문집
2016 .08
-
건선의 생물학제제 교체치료
대한건선학회지
2018 .01
-
Biologic mesh
대한외과학회 학술대회 초록집
2016 .11
-
Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
Journal of Korean Medical Science
2023 .06
-
중등도와 중증의 건선환자에서 생물학제제 치료 후 치료 만족도에 대한 평가
대한건선학회지
2021 .12
-
Which areas are still left in biologics responsive Korean patients with moderate to severe plaque psoriasis
Annals of Dermatology
2023 .02
-
Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
Cancer Research and Treatment
2024 .07
-
Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease
Pediatric Gastroenterology, Hepatology & Nutrition
2019 .01
-
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
Intestinal research
2023 .01
-
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Intestinal research
2019 .01
-
Health Care Utilization and Expenditures of Patients with Diabetes Comorbid with Depression Disorder: A National Population-Based Cohort Study
PSYCHIATRY INVESTIGATION
2017 .01
-
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Intestinal research
2018 .01
-
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Intestinal research
2019 .01
-
정밀한 천식 치료를 위한 생물학적 제제
Allergy Asthma & Respiratory Diseases
2019 .01
-
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal research
2023 .01
-
Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine
Annals of Laboratory Medicine
2020 .01
최근 본 자료
댓글(0)
0